Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Craig L Slingluff, Jr.; Gina R Petroni; Kimberly A Chianese-Bullock; Nolan A Wages; Walter C Olson; Kelly T Smith; Kathleen Haden; Lynn T Dengel; Anna Dickinson; Caroline Reed; Elizabeth M Gaughan; William W Grosh; Varinder Kaur; Nikole Varhegyi; Mark Smolkin; Nadejda V Galeassi; Donna Deacon; Emily H Hall

doi:10.1136/jitc-2020-000934

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Authors

Craig L Slingluff, Jr. Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USAUniversity of Virginia Cancer Center, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Gina R Petroni University of Virginia Cancer Center, Charlottesville, Virginia, USAPublic Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Kimberly A Chianese-Bullock Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USAUniversity of Virginia Cancer Center, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Nolan A Wages University of Virginia Cancer Center, Charlottesville, Virginia, USAPublic Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Walter C Olson Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Kelly T Smith Office of Research Cores Administration, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Kathleen Haden University of Virginia Cancer Center, Charlottesville, Virginia, USAUniversity of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Lynn T Dengel Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USAUniversity of Virginia Cancer Center, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Anna Dickinson Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Caroline Reed Department of Gynecology and Obstetrics, Emory University, Atlanta, GA, USA PubMed articles Google scholar articles
Elizabeth M Gaughan Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
William W Grosh Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Varinder Kaur Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Nikole Varhegyi Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Mark Smolkin Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Nadejda V Galeassi Cardiovascular Imaging Center, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Donna Deacon Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USA PubMed articles Google scholar articles
Emily H Hall Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, USAUniversity of Virginia Cancer Center, Charlottesville, Virginia, USA PubMed articles Google scholar articles

Citation

Slingluff, Jr. CL, Petroni GR, Chianese-Bullock KA, et al

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63)

Journal for ImmunoTherapy of Cancer 2021;9:e000934. doi: 10.1136/jitc-2020-000934

Online issue publication

November 23, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password